Linagliptin is a DPP-4 inhibitor for type 2 diabetes that is unique in its class because it is primarily eliminated via the bile and gut rather than the kidneys. This means no dose adjustment is required in renal impairment, making it particularly useful in patients with chronic kidney disease.
Evidence rating strong. Most-documented uses: lowers hba1c by 0.5–0.7%, no dose adjustment needed for renal or hepatic impairment, weight neutral. 10 sources indexed (2019–2025), with 1 interaction record on file.
The science
How it works, mechanistically.
Core mechanism
Selectively inhibits dipeptidyl peptidase-4 (DPP-4), preventing degradation of incretin hormones GLP-1 and GIP. This leads to glucose-dependent increase in insulin secretion and decrease in glucagon levels, resulting in improved glycemic control without glucose-independent insulin stimulation.8
Class
DPP-4 Inhibitor
Dosing
Dosing & protocol.
Common range
5 mg once daily (as prescribed by your physician)
Recommended form
Oral tablet
Can be taken with or without food at any time of day.10
Safety
Full safety detail.
Side effects
Nasopharyngitis
Hypersensitivity reactions
Cough
Pancreatitis (rare)
Arthralgia
Back pain
Contraindications
Known hypersensitivity to linagliptin (anaphylaxis, angioedema, exfoliative skin conditions reported)1,2
Linagliptin is a DPP-4 inhibitor that lowers blood glucose by prolonging endogenous GLP-1 activity. Chromium improves insulin sensitivity. On linagliptin alone the hypoglycemia risk is low, but additive effects matter when chromium is added on top of insulin or a sulfonylurea.
Recommendation: If linagliptin is your only diabetes medication, chromium can be added with home glucose monitoring for the first 2-4 weeks. If you also take insulin or a sulfonylurea, ask your prescriber whether those agents need to be reduced first.
Panda PS, Mohapatra I, Padhee S et al.. Renoprotective Action of Linagliptin Among Diabetic Kidney Disease Patients: A Systematic Review and Meta-Analysis. Cureus. 2025
Aljohani H, Alrubaish FS, Alghamdi WM et al.. Safety of Linagliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Therapeutic innovation & regulatory science. 2024
Wang MJ, Liu JL, Wang N et al.. The effectiveness and safety of linagliptin within elderly type 2 diabetes mellitus: a meta-analysis and systematic review. Minerva endocrinology. 2024
Laffel LM, Danne T, Klingensmith GJ et al.. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. The lancet. Diabetes & endocrinology. 2023
Rosenstock J, Kahn SE, Johansen OE et al.. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Linagliptin in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack